Relive the excitement of the Patriots’ path to their fourth Super Bowl Championship with “Pumped”, a special commemorative book from The Boston Globe. Order now.

AstraZeneca says DOJ closes probe into drug trial

WASHINGTON — British drugmaker AstraZeneca says the Department of Justice has closed its investigation into a clinical trial of the company’s blood thinner Brilinta, and plans no further action.

The company announced in October 2013 that federal officials were looking into the 18,000-patient study, which began in 2009.

Continue reading below

The study, dubbed PLATO, showed that patients taking Brilinta instead of competing drug Plavix were less likely to experience various heart-related problems, including heart attack, stroke and death.

News of the investigation has raised questions about the validity of the trial and the benefits of the drug, which hit the market in 2011.

The London-based drugmaker said in a statement Tuesday: ‘‘AstraZeneca has always had absolute confidence in the integrity of the PLATO trial.’’

Brilinta had sales of $283 million last year.

 Correction: Because of an editing error, the headline on the print version of this story incorrectly characterized the status of the US inquiry into Brilinta.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking. Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com